成立于2015年的创新药企诺诚健华,见证了中国创新药飞速发展的十年。近期,“民企显身手奋进正当时”主题采访活动走进诺诚健华,探访其如何在十年间通过不断创新建立竞争优势。如今,诺诚健华已在血液瘤、自身免疫性疾病及实体瘤领域建立丰富产品管线,核心产品奥布替尼已实现商业化,在港股18A政策及科创板第五套政策的支持下,尚未实现盈利的诺诚健华已实现A+H两地上市。诺诚健华的发展历程,也是中国创新药近十年发展...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.